Sandoz (SDZNY) announced that the European Commission, or EC, has granted marketing authorization for Afqlir 2 mg vial kit and pre-filled ...

Sandoz's approval of Afqlir highlights their commitment to affordable, effective treatment options for retinal diseases.

Swiss generic and biosimilar medicines major Sandoz today announced that the European Commission (EC) has granted marketing ...

Aflibercept-Biosimilar FYB203 / AHZANTIVE®/ Baiama® receives positive CHMP Opinion from EMA ...

Looking at options history for Regeneron Pharmaceuticals REGN we detected 8 trades. If we consider the specifics of each ...

Statement/Regulatory AdmissionAflibercept-Biosimilar FYB203 / AHZANTIVE®/ Baiama® receives positive CHMP Opinion from EMA15-Nov-2024 / 18:18 CET/CESTDisclosure of an inside information acc. to Article ...

Afqlir® (aflibercept) approved to treat various retinal diseases, including neovascular age-related macular degeneration ...

Now, it's up to the European Commission to confirm those potential green lights in the coming weeks and months.

Afqlir is indicated to treat various retinal diseases, including neovascular age-related macular degeneration (nAMD) ...

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activity M ...

Kodiak's stock surged 160% since September 2023, despite initial setbacks with tarcocimab in diabetic macular edema studies.

The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, ...